ProfileGDS5678 / 1434121_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 32% 32% 32% 31% 30% 33% 33% 32% 33% 32% 38% 31% 32% 32% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.7545432
GSM967853U87-EV human glioblastoma xenograft - Control 22.7362732
GSM967854U87-EV human glioblastoma xenograft - Control 32.7333232
GSM967855U87-EV human glioblastoma xenograft - Control 42.6526231
GSM967856U87-EV human glioblastoma xenograft - Control 52.6439330
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.8251133
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.8084433
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.713532
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.7196733
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.7071532
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.8584338
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.6791531
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.7346732
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.7222532